Navigation Links
UT MD Anderson discovery wins 2010 Cozzarelli Prize

HOUSTON - While studying one tumor-suppressing protein, Cheryl Walker's research team at The University of Texas MD Anderson Cancer Center came across a separate surprise. They found another protective protein known to work inside the cell nucleus moonlighting out in the cell's cytoplasm.

Following up on this unexpected observation, they discovered the cancer-blocking nuclear protein ATM has a second job controlling and killing damaged cells in the area between the nucleus and the cell membrane. Both functions stymie cancer by preventing reproduction of defective cells.

Their groundbreaking paper in the Proceedings of the National Academy of the Sciences has been chosen for the Cozzarelli Prize as the best paper in the Biological Science category published in the Proceedings during 2010. The prizes are given to the top paper in six categories out of more than 3,700 studies published by the journal each year.

"The Cozzarelli Prize is wonderful recognition of research that brought to light a brand new aspect of cell biology and marked a new direction for our lab," said Walker, a Ph.D. and professor in the Department of Molecular Carcinogenesis. The department is located at MD Anderson's Virginia Harris Cockrell Cancer Research Center, Science Park, near Smithville, Texas.

"Discovery of ATM's additional anti-tumor role is the type of basic science research that heightens our understanding of cancer and paves the way for improved prevention and treatment," said Raymond DuBois, M.D., Ph.D., MD Anderson provost and executive vice president. "The Cozzarelli Prize is a great honor for Cheryl, her lab and MD Anderson.

"The award also highlights the opportunities available for graduate students at MD Anderson," DuBois said. Co-first author Angela Alexander is a doctoral student in The University of Texas Graduate School of Biomedical Sciences, which is operated jointly by MD Anderson and The University of Texas Health Science Center at Houston (UTHealth).

"The initial discovery by postdoctoral fellow Shengli Cai, Ph.D., Angela's first authorship and excellent collaboration with scientists at other institutions all made this a great project," Walker said.

The team discovered that ATM (short for Ataxia-Telangiectasia Mutated) recognizes damage caused by reactive oxygen species (ROS) in the cytoplasm and tells the cell to stop growing or orders the cell to consume itself, a process called autophagy.

Reactive oxygen species are a byproduct of cellular metabolism. They react with other molecules, are toxic in large amounts and kept in check by antioxidants. When that balance is disrupted, elevated ROS levels damage proteins, lipids and DNA.

Elevated ROS has been linked to more than 150 diseases, including diabetes, cancer, neurodegenerative diseases and atherosclerosis.

In its previously known role, ATM notices DNA damage, orders the cell to repair the damage and halts cell division. If repair is not possible, ATM sets off apoptosis - programmed cell death. ATM is commonly mutated in cancer.

ATM sets off a molecular chain of events to kill ROS-damaged cells that includes the tumor-suppressor TSC2, the protein originally targeted by the researchers.

One possibility raised by this research, Walker said, is the ability to activate ATM without damaging DNA.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Khalifa Foundation grants MD Anderson $150 million for cancer research
2. Peers elect MD Andersons Hung and Lozano as Fellows of AAAS
3. NIH award goes to UT MD Anderson imaging innovator Guerrero
4. MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer
5. UT MD Anderson study finds women treated for breast cancer while pregnant have improved survival
6. MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey
7. Peg Fields to receive MD Andersons highest nurse-oncologist honor
8. Anderson & Kriger Takes Donations to Families Affected by Baja's Easter Earthquake
9. NACDS' Anderson Says Retailers and Suppliers' “Health and Wellness Renaissance” is Creating a “Historic, Watershed Moment”
10. M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer
11. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
Post Your Comments:
Related Image:
UT MD Anderson discovery wins 2010 Cozzarelli Prize
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: